12 results on '"BrÅthen, Geir"'
Search Results
2. The Norwegian Cognitive impairment after stroke study (Nor-COAST): study protocol of a multicentre, prospective cohort study
- Author
-
Thingstad, Pernille, Askim, Torunn, Beyer, Mona K., Bråthen, Geir, Ellekjær, Hanne, Ihle-Hansen, Hege, Knapskog, Anne Brita, Lydersen, Stian, Munthe-Kaas, Ragnhild, Næss, Halvor, Pendlebury, Sarah T., Seljeseth, Yngve Muller, and Saltvedt, Ingvild
- Published
- 2018
- Full Text
- View/download PDF
3. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
- Author
-
Giannisis, Andreas, Al-Grety, Asma, Carlsson, Henrik, Patra, Kalicharan, Twohig, Daniel, Sando, Sigrid Botne, Lauridsen, Camilla, Berge, Guro, Grøntvedt, Gøril Rolfseng, Bråthen, Geir, White, Linda R., Kultima, Kim, and Nielsen, Henrietta M.
- Subjects
APOLIPOPROTEIN E4 ,APOLIPOPROTEIN E ,ALZHEIMER'S disease ,MILD cognitive impairment ,AMNESTIC mild cognitive impairment ,TAU proteins ,DISEASE risk factors - Abstract
Background: Low levels of plasma apolipoprotein E (apoE) and presence of the APOE ε4 allele are associated with an increased risk of Alzheimer's disease (AD). Although the increased risk of AD in APOE ε4-carriers is well-established, the protein levels have received limited attention. Methods: We here report the total plasma apoE and apoE isoform levels at baseline from a longitudinally (24 months) followed cohort including controls (n = 39), patients with stable amnestic mild cognitive impairment during 24 months follow up (MCI-MCI, n = 30), patients with amnestic MCI (aMCI) that during follow-up were clinically diagnosed with AD with dementia (ADD) (MCI-ADD, n = 28), and patients with AD with dementia (ADD) at baseline (ADD, n = 28). We furthermore assessed associations between plasma apoE levels with cerebrospinal fluid (CSF) AD biomarkers and α-synuclein, as well as both CSF and plasma neurofilament light chain (NfL), YKL-40 and kallikrein 6. Results: Irrespective of clinical diagnosis, the highest versus the lowest apoE levels were found in APOE ε2/ε3 versus APOE ε4/ε4 subjects, with the most prominent differences exhibited in females. Total plasma apoE levels were 32% and 21% higher in the controls versus MCI-ADD and ADD patients, respectively. Interestingly, MCI-ADD patients exhibited a 30% reduction in plasma apoE compared to MCI-MCI patients. This decrease appeared to be associated with brain amyloid-β (Aβ
42 ) pathology regardless of disease status as assessed using the Amyloid, Tau, and Neurodegeneration (A/T/N) classification. In addition to the association between low plasma apoE and low levels of CSF Aβ42 , lower apoE levels were also related to higher levels of CSF total tau (t-tau) and tau phosphorylated at Threonine 181 residue (p-tau) and NfL as well as a worse performance on the mini-mental-state-examination. In MCI-ADD patients, low levels of plasma apoE were associated with higher levels of CSF α-synuclein and kallikrein 6. No significant correlations between plasma apoE and the astrocytic inflammatory marker YKL40 were observed. Conclusions: Our results demonstrate important associations between low plasma apoE levels, Aβ pathology, and progression from aMCI to a clinical ADD diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up.
- Author
-
Grøntvedt, Gøril Rolfseng, Lauridsen, Camilla, Berge, Guro, White, Linda R., Salvesen, Øyvind, Bråthen, Geir, and Sando, Sigrid Botne
- Subjects
AMNESTIC mild cognitive impairment ,AMYLOID ,ALZHEIMER'S disease ,NEURODEGENERATION ,CEREBROSPINAL fluid ,DISEASE progression ,RESEARCH ,NERVE tissue proteins ,PROGNOSIS ,EVALUATION research ,COMPARATIVE studies ,PEPTIDES ,LONGITUDINAL method ,AMNESIA - Abstract
Background: The unbiased amyloid, tau, and neurodegeneration (A/T/N) classification is designed to characterize individuals in the Alzheimer continuum and is currently little explored in clinical cohorts.Objective: A retrospective comparison of the A/T/N classification system with the results of a two-year clinical study, with extended follow-up up to 10 years after inclusion.Methods: Patients (n = 102) clinically diagnosed as Alzheimer's disease (AD) with dementia or amnestic mild cognitive impairment (MCI), and 61 cognitively healthy control individuals were included. Baseline cerebrospinal fluid core biomarkers for AD (Aβ42, phosphorylated tau, and total tau) were applied to the A/T/N classification using the final clinical diagnosis at extended follow-up as the gold standard.Results: A + T + N+ was a strong predictor for AD dementia, even among cognitively healthy individuals. Amnestic MCI was heterogenous, considering both clinical outcome and distribution within A/T/N. Some individuals with amnestic MCI progressed to clinical AD dementia within all four major A/T/N groups. The highest proportion of progression was among triple positive cases, but progression was also common in individuals with suspected non-Alzheimer pathophysiology (A-T + N+), and those with triple negative status. A-T-N- individuals who were cognitively healthy overwhelmingly remained cognitively intact over time, but in amnestic MCI the clinical outcome was heterogenous, including AD dementia, other dementias, and recovery.Conclusion: The A/T/N framework accentuates biomarkers over clinical status. However, when selecting individuals for research, a combination of the two may be necessary since the prognostic value of the A/T/N framework depends on clinical status. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease.
- Author
-
Patra, Kalicharan, Giannisis, Andreas, Edlund, Anna K., Sando, Sigrid Botne, Lauridsen, Camilla, Berge, Guro, Grøntvedt, Gøril Rolfseng, Bråthen, Geir, White, Linda R., Nielsen, Henrietta M., and Nacmias, Benedatta
- Subjects
APOLIPOPROTEIN E ,ALZHEIMER'S disease ,MONOMERS ,MILD cognitive impairment ,HIGH density lipoproteins ,CHOLESTERYL ester transfer protein - Abstract
The APOEɛ4 gene variant is the strongest genetic risk factor for Alzheimer's disease (AD), whereas APOEɛ3 conventionally is considered as 'risk neutral' although APOEɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOEɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOEɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOEɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOEɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOEɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOEɛ3 subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
- Author
-
Fladby, Tormod, Hessen, Erik, Eliassen, Carl Fredrik, Eriksson, Cecilia Magdalena, Aarsland, Dag, Kirsebom, Bjørn-Eivind, Waterloo, Knut K., Nakling, Arne Exner, and Bråthen, Geir
- Abstract
Background: In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI) criterion that discriminates well between normal and pathological aging.Objective: To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF) biomarkers for cognitive decline and dementia in persons seeking help for cognitive problems.Methods: 452 consecutively recruited patients (age 40-80 years) from memory-clinics in the Norwegian national multicentre longitudinal study Dementia Disease Initiation were included. CSF data as well as full data from brief neuropsychological screening were available for all patients.Results: Amnestic MCI, including at least one memory test below T-score 40, outperformed the conventional US National Institute on Aging-Alzheimer's Association (NIA-AA) MCI criterion. Only amnestic MCI was significantly associated with biomarker pattern of NIA-AA stage 2 (low CSF Aβ42 concentrations and elevated tau) in multivariate regression analysis.Conclusions: The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia. The prevalence of pathological biomarkers for Alzheimer's disease is common in the elderly and the clinical significance of present findings depend on longitudinal validation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Detecting At-Risk Alzheimer's Disease Cases.
- Author
-
Fladby, Tormod, Pålhaugen, Lene, Selnes, Per, Waterloo, Knut, Bråthen, Geir, Hessen, Erik, Almdahl, Ina Selseth, Arntzen, Kjell-Arne, Auning, Eirik, Eliassen, Carl Fredrik, Espenes, Ragna, Grambaite, Ramune, Rolfseng Grøntvedt, Gøril, Kunszt Johansen, Krisztina, Johnsen, Stein Harald, Kalheim, Lisa Flem, Kirsebom, Bjørn-Eivind, Müller, Kai Ivar, Nakling, Arne Exner, and Rongve, Arvid
- Subjects
ALZHEIMER'S disease ,SENILE dementia ,ALZHEIMER'S disease risk factors ,GENOTYPES ,COGNITIVE ability ,ALZHEIMER'S disease diagnosis ,APOLIPOPROTEINS ,COGNITION disorders ,COMPARATIVE studies ,NEUROPSYCHOLOGICAL tests ,RESEARCH methodology ,MEDICAL cooperation ,PEPTIDES ,PSYCHOLOGICAL tests ,RESEARCH ,SELF-evaluation ,EVALUATION research ,DISEASE progression ,DISEASE complications - Abstract
While APOEɛ4 is the major genetic risk factor for Alzheimer's disease (AD), amyloid dysmetabolism is an initial or early event predicting clinical disease and is an important focus for secondary intervention trials. To improve identification of cases with increased AD risk, we evaluated recruitment procedures using pathological CSF concentrations of Aβ42 (pAβ) and APOEɛ4 as risk markers in a multi-center study in Norway. In total, 490 subjects aged 40-80 y were included after response to advertisements and media coverage or memory clinics referrals. Controls (n = 164) were classified as normal controls without first-degree relatives with dementia (NC), normal controls with first-degree relatives with dementia (NCFD), or controls scoring below norms on cognitive screening. Patients (n = 301) were classified as subjective cognitive decline or mild cognitive impairment. Subjects underwent a clinical and cognitive examination and MRI according to standardized protocols. Core biomarkers in CSF from 411 and APOE genotype from 445 subjects were obtained. Cases (both self-referrals (n = 180) and memory clinics referrals (n = 87)) had increased fractions of pAβ and APOEɛ4 frequency compared to NC. Also, NCFD had higher APOEɛ4 frequencies without increased fraction of pAβ compared to NC, and cases recruited from memory clinics had higher fractions of pAβ and APOEɛ4 frequency than self-referred. This study shows that memory clinic referrals are pAβ enriched, whereas self-referred and NCFD cases more frequently are pAβ negative but at risk (APOEɛ4 positive), suitable for primary intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.
- Author
-
Almdahl, Ina S., Lauridsen, Camilla, Selnes, Per, Kalheim, Lisa F., Coello, Christopher, Gajdzik, Beata, Møller, Ina, Wettergreen, Marianne, Grambaite, Ramune, Bjørnerud, Atle, Bråthen, Geir, Sando, Sigrid B., White, Linda R., and Fladby, Tormod
- Subjects
CEREBROSPINAL fluid ,AMYLOID beta-protein ,BIOMARKERS ,ALZHEIMER'S disease ,POSITRON emission tomography - Abstract
Introduction: Amyloid beta 1-43 (Aβ43), with its additional C-terminal threonine residue, is hypothesized to play a role in early Alzheimer's disease pathology possibly different from that of amyloid beta 1-42 (Aβ42). Cerebrospinal fluid (CSF) Aβ43 has been suggested as a potential novel biomarker for predicting conversion from mild cognitive impairment (MCI) to dementia in Alzheimer's disease. However, the relationship between CSF Aβ43 and established imaging biomarkers of Alzheimer's disease has never been assessed. Materials and Methods: In this observational study, CSF Aβ43 was measured with ELISA in 89 subjects; 34 with subjective cognitive decline (SCD), 51 with MCI, and four with resolution of previous cognitive complaints. All subjects underwent structural MRI; 40 subjects on a 3T and 50 on a 1.5T scanner. Forty subjects, including 24 with SCD and 12 with MCI, underwent
18 F-Flutemetamol PET. Seventy-eight subjects were assessed with18 F-fluorodeoxyglucose PET (21 SCD/7 MCI and 11 SCD/39 MCI on two different scanners). Ten subjects with SCD and 39 with MCI also underwent diffusion tensor imaging. Results: Cerebrospinal fluid Abβ3 was both alone and together with p-tau a significant predictor of the distinction between SCD and MCI. There was a marked difference in CSF Aβ43 between subjects with18 F-Flutemetamol PET scans visually interpreted as negative (37 pg/ml, n = 27) and positive (15 pg/ml, n = 9), p < 0.001. Both CSF Aβ43 and Aβ42 were negatively correlated with standardized uptake value ratios for all analyzed regions; CSF Aβ43 average rho -0.73, Aβ42 -0.74. Both CSF Aβ peptides correlated significantly with hippocampal volume, inferior parietal and frontal cortical thickness and axial diffusivity in the corticospinal tract. There was a trend toward CSF Aβ42 being better correlated with cortical glucose metabolism. None of the studied correlations between CSF Aβ43/42 and imaging biomarkers were significantly different for the two Aβ peptides when controlling for multiple testing. Conclusion: Cerebrospinal fluid Aβ43 appears to be strongly correlated with cerebral amyloid deposits in the same way as Aβ42, even in non-demented patients with only subjective cognitive complaints. Regarding imaging biomarkers, there is no evidence from the present study that CSF Aβ43 performs better than the classical CSF biomarker Aβ42 for distinguishing SCD and MCI. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
9. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.
- Author
-
Berge, Guro, Sando, Sigrid B., Albrektsen, Grethe, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, and White, Linda R.
- Subjects
SYNUCLEINS ,ALZHEIMER'S disease ,MILD cognitive impairment ,ENZYME-linked immunosorbent assay ,ANALYSIS of variance ,AMYLOID - Abstract
Background: α-Synuclein has been proposed as a potential biomarker for Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes prior to the AD diagnosis have not been investigated. Methods: Levels of α-synuclein at baseline and after one and two years were measured in CSF, by enzyme-linked immunosorbent assay. Twenty-six patients with early AD (AD-AD), 48 patients with aMCI, subdivided as 23 that developed AD during follow-up (MCI-AD), and 25 that did not (MCI-MCI), and 25 healthy control individuals, were included. One-way ANOVA was applied to compare mean α-synuclein baseline values between all four study groups, and a linear mixed model was used to compare mean change over time between the three patient groups. Linear associations between α-synuclein and amyloid-β 1-42 (Aβ42), amyloid-β 1-40 (Aβ40), total tau and phosphorylated tau were also examined. Results: A large variation in individual α-synuclein CSF levels was observed, particularly in the MCI-AD group. No significant differences were found in mean α-synuclein levels between all the study groups at baseline. When using a linear mixed model, no significant differences were found at follow-up for estimated mean changes between the patient groups. MCI-AD patients with short duration of symptoms prior to inclusion in the study (=2 years) had considerably higher mean CSF α-synuclein levels compared to patients with a longer symptom duration (802.2 vs. 442.8 pg/mL, p = 0.01). No such difference was seen in the MCI-MCI or AD-AD groups. Significant linear associations (p < 0.0005) between α-synuclein and Aβ40, total tau and phosphorylated tau were found. Conclusion: The observed difference in mean CSF α-synuclein level according to duration of symptoms in the MCI-AD group, may be an indication of changes related to disease progression. However, the lack of significant differences between groups, as well as the large individual variation in CSF levels of α-synuclein in the present study, suggest that α-synuclein is not a useful biomarker for AD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
- Author
-
Lauridsen, Camilla, Sando, Sigrid B., Shabnam, Adiba, Møller, Ina, Berge, Guro, Grøntvedt, Gøril R., Bakken, Inger J., Salvesen, Øyvind, Bråthen, Geir, and White, Linda R.
- Subjects
ALZHEIMER'S disease research ,CEREBROSPINAL fluid ,AMYLOID beta-protein ,MILD cognitive impairment ,ENZYME-linked immunosorbent assay ,BIOMARKERS - Abstract
Introduction: Biomarkers that will reliably predict the onset of Alzheimer's disease (AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1-42 (Aß42), total tau, and phosphorylated tau can be used to complement the clinical diagnosis of AD, amnestic mild cognitive impairment (aMCI), the prodromal phase of AD, is heterogeneous. Biomarkers should be able to determine which patients with aMCI are at greatest risk of AD. Histological studies and animal models indicate that amyloid beta 1-43 (Aß43) aggregates early, and may play a role in the pathological process of AD. We have examined levels of CSF Aß43 in a 2-year longitudinal study of aMCI and early AD. Materials and Methods: Cerebrospinal fluid was collected at baseline, and after one and 2 years from patients with AD (n D 19), and patients with aMCI (n D 42). Of these, 21 progressed to AD during the 2 years of study, whereas 21 did not. Controls (n D 32) were lumbar punctured at baseline only. CSF analyses of Aß43, Aß42, and total tau were carried out with ELISA. Results: At baseline, CSF Aß43, CSF Aß42 and ratios with total tau could be used to separate controls from all three patient groups. CSF Aß43, but not Aß42, could separate patients with aMCI who progressed to AD during the 2 years of follow-up, from those that did not. The CSF total tau/Aß43 ratio had a slightly but significantly larger area under the receiver operating characteristic curve when compared to the CSF total tau/Aß42 ratio. CSF Aß43 levels, but not Aß42 levels, decreased from baseline to 2 years in the AD group. Discussion and Conclusion: CSF Aß43 was demonstrated to be significantly reduced in patients already by the time that aMCI or AD was diagnosed, compared to controls, and this change must have occurred during the preclinical period. Since our results suggested that CSF Aß43 distinguishes between subgroups of patients with aMCI better than CSF Aß42, it may prove to be a useful additional biomarker for identifying aMCI patients at greatest risk of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.
- Author
-
Berge, Guro, Lauridsen, Camilla, Sando, Sigrid Botne, Holder, Daniel Joseph, M÷ller, Ina, Aasly, Jan Olav, Bråthena, Geir, Savage, Mary Josephine, White, Linda Rosemary, Møller, Ina, and Bråthen, Geir
- Subjects
CEREBROSPINAL fluid examination ,BIOMARKERS ,ALZHEIMER'S disease ,MILD cognitive impairment ,PHOSPHORYLATION ,ALIQUOTS (Chemistry) ,COGNITION disorders ,ENZYME-linked immunosorbent assay ,LONGITUDINAL method ,NERVE tissue proteins ,PEPTIDES ,SURFACE active agents ,RECEIVER operating characteristic curves - Abstract
Background: There is substantial variation caused by preanalytical procedures in the measurement of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) reported in the literature.Objective: Determine whether the detergent Tween-20 improves diagnostic accuracy.Methods: CSF proteins (Aβ42, Aβ40, total tau, and phosphorylated tau) were measured by standard ELISA, in uncentrifuged CSF with or without 0.05% Tween-20 from patients with AD or amnestic mild cognitive impairment, and healthy elderly controls. In the main study, collection tubes containing Tween-20 (Sarstedt 15 mL) were filled with 5 mL CSF to ensure consistent detergent concentration across subsequent aliquots into Corning 2 mL tubes. These latter were also the primary collection vessel for samples without Tween-20. The effect of centrifugation, and extra tube transfer of samples with Tween-20 were also examined.Results: 0.05% Tween-20 significantly increased mean measured CSF concentration of Aβ42 (30% ), Aβ40 (23% ), and total tau (4% ), but not phosphorylated tau. Generally, these increases were similar in all groups, although for Aβ42, the mean percentage increase with Tween-20 was slightly larger for AD. Areas under receiver-operator characteristic curves were similar whether Tween-20 was present or not. Centrifuged CSF without Tween-20 significantly reduced the measured concentration of Aβ42 versus non-centrifuged samples, a difference not seen when detergent was added. Similar CSF Aβ42 levels were found whether Tween-20 was added at collection in an extra tube or directly to the main collection tube.Conclusion: Addition of Tween-20 to CSF did not improve differentiation of patients from controls. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study.
- Author
-
Lim, Bryant, Sando, Sigrid Botne, Grøntvedt, Gøril Rolfseng, Bråthen, Geir, and Diamandis, Eleftherios P.
- Subjects
- *
ALZHEIMER'S disease , *CEREBROSPINAL fluid , *ENZYME-linked immunosorbent assay , *MILD cognitive impairment - Abstract
Lower cerebrospinal fluid (CSF) levels of neuronal pentraxin receptor (NPTXR) are associated with Alzheimer's disease (AD), but few studies show longitudinal changes in CSF NPTXR. In the present study, CSF NPTXR was measured at 0, 12, and 24 months using an enzyme-linked immunosorbent assay. The study groups included 28 patients with mild cognitive impairment (MCI) (MCI-MCI), 27 MCI patients who progressed to AD (MCI-AD) during the study, and 28 AD patients (AD-AD). Baseline levels were assessed for 46 control individuals. AD patients had lower baseline CSF NPTXR than controls (p = 0.023). Linear mixed models estimated a 6.7% annualized decrease in CSF NPTXR in the AD-AD group, significantly different from MCI-MCI (p = 0.03) and MCI-AD groups (p = 0.048). CSF NPTXR did not correlate with CSF Aβ42 and weakly correlated with CSF Aβ40, T-tau, P-tau (all R2 < 0.22, p < 0.06). These trends suggest CSF NPTXR may be a candidate biomarker of AD progression but not sufficiently sensitive to resolve when patients convert from MCI to dementia. • Neuronal pentraxin receptor (NPTXR) decreased in Alzheimer's disease (AD) patients. • Annual decrease of NPTXR by 6.7% only in AD patients and not in mild cognitive impairment patients. • NPTXR associated with duration of AD symptoms. • NPTXR in cerebrospinal fluid may be useful for monitoring AD patients over time. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.